ADMA Biologics, Inc. (ADMA)
| Market Cap | 4.27B |
| Revenue (ttm) | 488.56M |
| Net Income (ttm) | 209.45M |
| Shares Out | 238.00M |
| EPS (ttm) | 0.86 |
| PE Ratio | 20.95 |
| Forward PE | 21.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,542,212 |
| Open | 17.80 |
| Previous Close | 17.95 |
| Day's Range | 16.24 - 18.20 |
| 52-Week Range | 13.50 - 25.67 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 28.50 (+58.95%) |
| Earnings Date | Mar 2, 2026 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ADMA stock is "Strong Buy." The 12-month stock price target is $28.5, which is an increase of 58.95% from the latest price.
News
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reitera...
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedica...
ADMA Biologics: Why The Dip To $16 Resets The Buy Case
ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITD...
ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
ADMA Biologics, Inc. ( ADMA) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Adam Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Conference Call ...
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjust...
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
3 Biotech Stocks I Am Accumulating
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra...
ADMA Biologics: Strong Product Mix, Growing Margins And Compelling Upside
ADMA Biologics' earnings are surging due to higher plasma yield and a profitable shift toward premium IG brands, boosting margins. FDA approval of yield-enhancement technology increases finished IG ou...
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform
ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yie...
ADMA Biologics: A Better Quarter Than Headline Numbers
ADMA Biologics experienced a significant stock pullback on Thursday after Q2 results, presenting a potential buying opportunity for investors. The company now operates 10 plasma collection centers and...
ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Adam S. Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer...
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)
ADMA's revenue growth has plateaued over the last three quarters, raising concerns about near-term momentum and justifying a shift to a neutral stance. Despite strong fundamentals and a promising long...
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY r...
ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossm...
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1) of $118.6 Million), a 40% YoY Increase
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain Reiterates Strategic Advanta...
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-ov...
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
Block & Leviton is investigating ADMA Biologics for potential securities fraud. Investors who lost money in ADMA should contact the firm to learn more.
ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Gros...
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA (1) of $164.6 ...